“The good physician treats the disease; the great physician treats the patient who has the disease”

— Sir William Osler

"Health equity is not just a goal; it is a fundamental human right."

— Dr. Paul Farmer

Christine Kohn, MD, PharmD

Director of Population Health Strategy, Concierge Physician

Contact:

DrKohn@bespokeconciergemd.com

Experience:

15+ years

Areas of Specialty:

Public Health
Hospital Medicine
Pharmacy
Mental health
Weight Management
Women
Oncology
AI Integration
Primary Care
Care System Design

Certifications & Education

Doctor of Pharmacy, Honors Scholar: University of Connecticut, School of Pharmacy
Doctor of Medicine: University of Connecticut, School of Medicine
Board Certified in Internal Medicine (ABIM)
Fellowship in Health Economics and Outcomes Research: University of Connecticut School of Pharmacy & Hartford Hospital Evidence-Based Practice Center
Clinical Fellow in Medicine, Harvard Medical School
Masters of Public Health (Candidate), Harvard TH Chan Schol of Public Health

Meet Christine Kohn, MD, PharmD

My work in medicine is shaped by caring for patients at their most vulnerable moments and by improving the systems that serve them. I believe the best care is personal, evidence-driven, and intentionally designed to be accessible.

— Christine Kohn, MD, PharmD

Bio:

Dr. Christine Kohn is a physician, pharmacist, health economist, and healthcare strategist whose career spans Internal Medicine, Pharmacy, health policy, and outcomes research. As Director of Population Health Strategy at Bespoke Concierge MD, she leads the development of data-informed, value-based care models that align high-touch concierge medicine with scalable population health impact, focusing on leveraging clinical insight, rigorous analytics, and digital innovation to design care pathways that are both patient-centered and operationally sustainable.

‍

Dr. Kohn is known for building well-rounded, cross-functional programs that integrate clinical operations, quality and safety initiatives, and payment strategy into cohesive, high-performing care models. She has led initiatives in value-based care, women’s health, and virtual-first primary care that combine real-world data, workflow redesign, and team-based care to improve outcomes while supporting clinician experience and financial sustainability. Her work in health economics and outcomes research, including more than 40 peer-reviewed publications, underpins a deeply analytical approach to program design, ensuring that innovation is grounded in evidence and measurable impact.

‍

A strong believer in the strategic use of technology, Dr. Kohn has hands-on experience incorporating conversational AI, remote care, and integrated claims and clinical data into outpatient workflows. She has advised digital health startups and health plans on go-to-market strategy, population segmentation, and care model design, helping organizations translate complex analytics into practical, clinician-friendly tools and scalable programs. Her program-building emphasizes thoughtful governance, change management, and user-centered design so that advanced analytics and AI augment, rather than replace, the human relationships at the heart of medicine.

‍

Dr. Kohn holds MD and PharmD degrees from the University of Connecticut and completed an AHRQ-funded fellowship in Health Economics and Outcomes Research before training in Internal Medicine at Beth Israel Deaconess Medical Center / Harvard Medical School. She serves as an Instructor in Medicine at Harvard Medical School, a primary care physician at Massachusetts General Hospital, and the David F. Torchiana Fellow in Health Policy and Management at Mass General Brigham, roles that give her a unique vantage point on how policy, payment, and frontline care intersect. At Bespoke Concierge MD, she brings this multifaceted expertise to architect learning health systems and population health strategies that connect concierge-level care with broader gains in access, equity, and value.

About the provider

Articles

No items found.

No articles found for this provider.

Media Interviews

Publications:

1. Costa OS, Kohn CG, Kuderer NM, Lyman GH, Bunz TJ, Coleman CI. Effectiveness and Safety of Rivaroxaban Compared to Low Molecular Weight Heparin in Patients with Cancer-Associated Venous Thromboembolism: A Real World Analysis. Blood Adv. 2020 Sep 8;4(17):4045-4051.

2. Caranfa JT, Kohn CG, Baker WL, Waitzman DM. Monoclonal antibody therapy for neuromyelitis optica: a systematic review and meta-analysis. J Neurol Disord. 2019 Dec; 7(3): 412

3. Kohn CG, Alberts MJ, Peacock WF, Bunz TJ, Coleman CI. Cost and inpatient burden of peripheral artery disease: Findings from the National Inpatient Sample. Atherosclerosis. 2019 Jul;286:142-146. PMID: 31170647.

4. Dolinar R, Kohn CG, Lavernia F, Nguyen E. The non-medical switching of prescription medications. Postgrad Med. 2019 Jun;131(5):335-341. PMID: 31081414.

5. Weeda ER, Caranfa JT, Lyman GH, Kuderer NM, Nguyen E, Coleman CI, Kohn CG*. External validation of three risk stratification rules in patients presenting with pulmonary embolism and cancer. Support Care Cancer. 2019 Mar;27(3):921-925. PMID: 30090992

6. Kohn CG, Singh P, Korytowsky B, Caranfa JT, Miller JD, Sill BE, Marshall AC, Parikh ND. Humanistic and economic burden of hepatocellular carcinoma: systematic literature review. Am J Manag Care. 2019 Feb;25(2 Spec No.):SP61SP73. PMID: 30776212.

7. Kohn CG, Bunz TJ, Beyer-Westendorf J, Coleman CI. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. Eur J Haematol. 2019 Feb;102(2):143-149. PMID: 30328143.

8. Nguyen E, Coleman CI, Kohn CG, Weeda ER. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. Int J Cardiol. 2018 Dec 15;273:34-38. PMID: 30266352

9. Nguyen E, Weeda ER, Kohn CG, D'Souza BA, Russo AM, Noreika S, Coleman CI. Wearable Cardioverterdefibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis. J Innov Card Rhythm Manag. 2018;9(5):3151‐3162. PMID: 32477809

10. Kohn CG, Lyman GH, Beyer-Westendorf J, Spyropoulos AC, Bunz TJ, Baker WL, Eriksson D, Meinecke AK, Coleman CI. Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. J Natl Compr Canc Netw. 2018 May;16(5):491-497. PMID: 29752323

11. Nguyen E, Caranfa JT, Lyman GH, Kuderer NM, Stirbis C, Wysocki M, Coleman CI, Weeda ER, Kohn CG*. Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis. J Thromb Haemost. 2018 Feb;16(2):279-292. PMID: 29215781.

12. Caranfa JT, Ali R, Francis I, Zichichi A, Bosco E, Coleman CI, Baker WL, Kohn CG*. Mechanical endovascular therapy for acute ischemic stroke: An indirect treatment comparison between Solitaire and Penumbra thrombectomy devices. PLoS One. 2018 Mar 7;13(3):e0191657. PMID: 29513676

13. Weeda EW, Caranfa JT, Zeichner SB, Coleman CI, Nguyen E, Kohn CG*. External Validation of Generic and CancerSpecific Risk Stratification Tools in Patients with Pulmonary Embolism and Active Cancer. J Natl Compr Canc Netw. 2017 Dec;15(12):1476-1482. PMID: 29223985 Updated 010/2024 Christine G. Kohn, MD PharmD Page 5 of 12

14. Weeda ER, Kohn CG, Peacock WF, Fermann GJ, Crivera C, Schein JR, Coleman CI. External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality. Clin Appl Thromb Hemost. 2017 Oct;23(7):769-774. PMID: 27225840

15. Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR. Reply to Á. Benedict et al. J Clin Oncol. 2017 Sep 10;35(26):3086-3087. PMID: 28715248

16. Kohn CG, Fermann GJ, Peacock WF, Wells PS, Baugh CW, Ashton V, Crivera C, Schein JR, Wildgoose P, Coleman CI. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Curr Med Res Opin. 2017 Sep;33(9):1697-1703. PMID: 28665208

17. Kohn CG, Weeda ER, Kumar N, Wells PS, Peacock WF, Fermann GJ, Wang L, Baser O, Schein JR, Crivera C, Coleman CI. External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. Intern Emerg Med. 2017 Aug;12(5):613-619. PMID: 28185131

18. Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CF. The Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol. 2017 Apr 10;35(11):1194-1202. PMID: 28221865

19. Nguyen E, Peacock WF, Fermann GJ, Ashton V, Concetta C, Wildgoose P, Schein JR, Coleman C, Kohn CG*. External Validation of the Multivariable ‘In-Hospital Mortality for Pulmonary Embolism Using Claims Data’ Prediction Rule in the Premier Hospital Database. Eur Heart J Qual Care Clin Outcomes. 2017 Apr 1;3(2):157-159. PMID: 28927177

20. Zeichner SB, Kohn CG, Goldstein DA. Economics of ramucirumab for metastatic colorectal cancer. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):733-745. PMID: 27828732

21. Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016 Nov;160(1):187-196. PMID: 27548074

22. Weeda ER, Kohn CG, Peacock WF, Fermann GJ, Crivera C, Schein JR, Coleman CI. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 Oct;36(10):1109-1115. PMID: 27548074

23. Rozjabek HM, Coleman CI, Weeda ER, Peacock WF, Fermann GJ, Crivera C, Schein JR, Kohn CG*. Effect of vital sign measurement timing on Pulmonary Embolism Severity Index (PESI) and simplified PESI 30-day mortality risk determination. Thromb Res. 2016 May;141:8-10. PMID: 26946105

24. Weeda ER, Kohn CG, Fermann GJ, Peacock WF, Tanner C, McGrath D, Crivera C, Schein JR, Coleman CI. External validation of prognostic rules for early post-pulmonary embolism mortality: assessment of a claims-based and three clinical-based approaches. Thromb J. 2016 Mar 14;14:7. PMID: 26977136

25. Diaby V, Ali AA, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic HER2-positive breast cancer patients. Curr Med Res Opin. 2016 Jun;32(6):991-6. PMID: 26824145

26. Kohn CG, Peacock FW, Fermann GJ, Bunz TJ, Crivera C, Shein JR, Coleman CI. External validation of the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) multivariable prediction rule. Int J Clin Pract. 2016 Jan;70(1):82-8. PMID: 26575855

27. Coleman CI, Freemantle N, Kohn CG*. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective. BMJ Open. 2015 Nov 6;5(11):e008861. PMID: 26546142

28. Coleman CI, Kohn CG, Crivera C, Schein JR, Peacock WF. Validation of the multivariable In-hospital Mortality for PulmonAry embolism using Claims data (IMPACT) prediction rule within an all-payer inpatient administrative claims database. BMJ Open. 2015 Oct 28;5(10):e009251. PMID: 26510731

29. Coleman CI, Kohn CG, Bunz TJ. Derivation and validation of the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule. Curr Med Res Opin. 2015 Aug 31(8) 1461-8. PMID: 26074196

30. Mearns ES, Saulsberry WJ, White CM, Kohn CG, Lemieux S, Sihabout A, Salamucha I, Coleman CI. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. Diabet Med. 2015 Dec;32(12):1530-40. PMID: 26104021 Updated 010/2024 Page 6 of 12 Christine G. Kohn, MD PharmD

31. Mearns ES, Coleman CI, Patel D, Saulsberry WJ, Corman A, Li D, Hernandez AV, Kohn CG*. Index Clinical Manifestation of Venous Thromboembolism Predicts Early Recurrence Type and Frequency: A Meta-Analysis of Randomized Controlled Trials. J Thromb Haemost. 2015 Jun;13(6):1043-52. PMID: 25819920

32. Mearns ES, Sobieraj DM, White CM, Saulsberry WJ, Kohn CG, Doleh Y, Zaccaro E, Coleman CI. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One. 2015 Apr 28;10(4):e0125879. PMID: 25919293

33. Kohn CG, Mearns EM, Parker MW, Hernandez AV, Coleman CI. Prognostic Accuracy of Clinical Prediction Rules for Early Post-Pulmonary Embolism All-Cause Mortality: A Bivariate Meta-Analysis. Chest. 2015 Apr 1;147(4):1043-62. PMID: 25317677

34. Kohn CG, Coleman CI, Michael White C, Sidovar MF, Sobieraj DM. Mobility, Walking and Physical Activity in Persons with Multiple Sclerosis. Curr Med Res Opin. 2014 Sep;30(9):1857-62. PMID: 24803286

35. Mearns ES, White CM, Kohn CG, Hawthorne J, Song JS, Meng J, Schein JR, Raut MK, Coleman CI. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014 Jun 24;12:14. PMID: 25024644

36. Mearns EM, Kohn CG, Song JS, Hawthorne J, Meng J, White CM, Raut MK, Schein JR, Coleman CI. Meta-Analysis to Assess the Quality of Vitamin K Antagonist Control and Associated Outcomes in Venous Thromboembolism Patients. Thrombosis Research. 2014 Aug;134(2):310-9. PMID: 24935672

37. Kohn CG, Parker MW, Limone BL, Coleman CI. Impact of Angina Frequency on Health Utility Values of Patients with Chronic Stable Angina. Health Qual Life Outcomes. 2014 Mar 14;12:39. PMID: 24628859

38. Kohn CG, Parker MW, Limone BL, Coleman CI. Cost-Effectiveness of Ranolazine Added to Standard-of-Care Treatment in Patients with Chronic Stable Angina Pectoris. Am J Cardiol. 2014 Apr 15;113(8):1306-11. PMID: 24560062

39. CG Kohn, H Salaheen, K Borrup, S Rogers, G Lapidus. Correlates of drugs use and driving among undergraduate college students. Traffic Inj Prev. 2014;15(2):119-24. PMID: 24345012.

40. Kohn CG, Sidovar MF, Kaur K, Zhu Y, Coleman CI. Estimating a Minimal Clinically Important Difference for the EuroQol 5-Dimension Health Status Index in Persons with Multiple Sclerosis. Health Qual Life Outcomes. 2014 May 5;12:66. PMID: 24886430

41. Kohn CG, Baker WL, Sidovar MF, Coleman CI. Walking Speed and Health‐Related Quality of Life in Multiple Sclerosis. The Patient. 2014;7(1):55-61. PMID: 24078332

42. CG Kohn, Azeem M, Kluger J, Coleman CI. Short-Term Consequences of Angiographically-Confirmed Coronary Stent Thrombosis. PLoS One. 2013. 15;8(10):e77330. PMID: 24143219

43. Coleman CI, Sidovar MF, Roberts MS, Kohn C. Impact of Mobility Impairment on Indirect Costs and Health-Related Quality of Life in Multiple Sclerosis. PLoS One. 2013;8(1):e54756. PMID: 23355896

‍

Bespoke Concierge MD

Quick Links

The Team

More Info

Subscribe to Our Newsletter